Clinical Trials Logo

Glaucoma, Neovascular clinical trials

View clinical trials related to Glaucoma, Neovascular.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT05593354 Not yet recruiting - Glaucoma Clinical Trials

MicroPulse TLT - UK Study

MPTLTUKS
Start date: May 1, 2023
Phase:
Study type: Observational [Patient Registry]

This Prospective Interventional Study will assess the efficacy of MPTLT in the UK.

NCT ID: NCT05316142 Not yet recruiting - Clinical trials for Neovascular Glaucoma

Any Unique Identifier Assigned to the Protocol by the Sponsor

Start date: August 1, 2024
Phase: N/A
Study type: Interventional

Neovascular glaucoma is a common and severe type of secondary closed-angle glaucoma. Topical treatments have variable effects and unfortunately often require surgery to control IOP. Although Glaucoma Drainage Device (GDD) such as Ahmed Glaucoma Valve (AGV) are a surgical choice in these patients, their effectiveness decreases over time. One of the main causes of failure in AGV surgery is the formation of scar tissue and fibrosis around the shunt plate. So, the aim of this study was to evaluate the effect of using MMC Intraoperative and 5FU Postoperative with AGV surgery in neovascular glaucoma patients according to a specific protocol, on the incidence of Hypertensive Phase (HP) and surgical success rate.

NCT ID: NCT02947867 Not yet recruiting - Clinical trials for Neovascular Glaucoma

Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG

STRONG
Start date: January 2017
Phase: Phase 2/Phase 3
Study type: Interventional

A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the STRONG Study

NCT ID: NCT02914626 Not yet recruiting - Clinical trials for Glaucoma, Neovascular

Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study

Start date: October 2016
Phase: Phase 3
Study type: Interventional

Neovascular glaucoma is a potentially blinding condition characterized by the growth of newvessels at the anterior part of the eye. This growth is driven by the overexpression of a protein called Vascular Endothelial Growth Factor (VEGF). That happens in diseases such as diabetic retinopathy or venous retinal occlusion, and lead to a fast increase in intraocular pressure (IOP). Traditional treatment include laser photocoagulation of the retina in order to decrease VEGF formation. The investigators postulate that the use of anti-VEGF intravitreal injections may accelerate recovery and decrease the need of surgery in cases of neovascular glaucoma.